GlassScriptPhysician profile
Jennifer N Eason
NPI 1134762362
$10,717.57
in general payments reported to CMS, 2019-2025
57 companies · $2,918 in 2025
The $2,918 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $148 · 2022: $1,713 · 2023: $2,550 · 2024: $3,389 · 2025: $2,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,659 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,658.87 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $925.00 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $807.54 | 2021-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $776.77 | 2022-2025 | Opdivo, Reblozyl |
| Daiichi Sankyo INC. | $738.35 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Eisai INC. | $500.51 | 2022-2025 | |
| Abbvie INC. | $488.16 | 2023-2025 | |
| Janssen Biotech, INC. | $477.12 | 2022-2025 | Rybrevant, Darzalex, Talvey |
| Amgen INC. | $458.38 | 2021-2024 | Nplate, Lumakras |
| Pfizer INC. | $396.91 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $339.90 | 2022-2025 | Tagrisso |
| Takeda Pharmaceuticals U.S.A., INC. | $325.12 | 2022-2025 | Fruzaqla, Iclusig, Ninlaro |
| Celgene Corporation | $312.33 | 2022-2025 | Pomalyst, Reblozyl, Opdualag |
| Genentech USA, INC. | $299.63 | 2023-2025 | Tecentriq, Phesgo, Itovebi |
| Seagen INC. | $280.20 | 2022-2023 | Padcev, Adcetris |
| Incyte Corporation | $277.09 | 2022-2025 | Jakafi, Monjuvi |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $275.01 | 2023-2025 | Monoferric, Cosela |
| Regeneron Healthcare Solutions, INC. | $274.31 | 2022-2025 | Libtayo |
| Lilly USA, LLC | $171.10 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $158.65 | 2023 | Trodelvy |
| Sun Pharmaceutical Industries INC. | $158.34 | 2022-2025 | Yonsa, Odomzo |
| Blueprint Medicines Corporation | $137.17 | 2022-2025 | Ayvakit |
| Genzyme Corporation | $137.10 | 2022-2025 | |
| Beigene USA, INC. | $135.77 | 2024 | Brukinsa |
| Astellas Pharma US INC | $119.03 | 2023-2025 | Xtandi, Padcev |
| Kyowa Kirin, INC. | $113.50 | 2022-2025 | Poteligeo |
| Aveo Pharmaceuticals, INC. | $108.88 | 2022-2025 | Fotivda |
| Tersera Therapeutics LLC | $108.47 | 2022-2025 | Zoladex |
| Coherus Oncology, INC. | $98.55 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.49 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.70 | 2025 | |
| Sumitomo Pharma America, INC. | $81.08 | 2023-2024 | Orgovyx |
| Rigel Pharmaceuticals, INC. | $75.21 | 2022-2024 | Tavalisse, Rezlidhia |
| Taiho Oncology, INC. | $74.59 | 2022-2025 | |
| G1 Therapeutics, INC. | $73.77 | 2022-2023 | Cosela |
| Stemline Therapeutics INC. | $68.99 | 2023-2025 | Orserdu |
| Pharmaessentia USA Corporation | $68.58 | 2023-2025 | Besremi |
| Cumberland Pharmaceuticals, INC. | $64.88 | 2022-2025 | Sancuso |
| Pharmacyclics LLC, An Abbvie Company | $62.14 | 2023 | Imbruvica, Epkinly |
| Kite Pharma, INC. | $56.86 | 2022-2023 | |
| Sobi, INC | $54.01 | 2022-2024 | |
| Array Biopharma INC | $50.18 | 2022-2025 | Mektovi, Braftovi, Xalkori |
| Morphosys, US INC. | $49.82 | 2022-2024 | Monjuvi |
| Karyopharm Therapeutics INC. | $49.12 | 2022-2024 | Xpovio |
| Puma Biotechnology, INC. | $39.32 | 2023-2024 | |
| Genmab U.S., INC. | $31.25 | 2023-2025 | Epkinly |
| Foundation Medicine, INC. | $30.23 | 2023 | Foundationone Liquid Cdx |
| Adc Therapeutics America, INC. | $29.77 | 2022-2023 | |
| Progenics Pharmaceuticals, INC. | $24.63 | 2024 | |
| Accord Healthcare, INC. | $22.30 | 2025 | |
| Adaptive Biotechnologies Corporation | $19.18 | 2023 | Clonoseq |
| Mirati Therapeutics, INC. | $18.92 | 2024 | Krazati |
| Glaxosmithkline, LLC. | $18.18 | 2025 | Blenrep, Ojjaara |
| Caris Mpi, INC. | $17.40 | 2025 | Mi Cancer Seek |
| Octapharma USA, INC. | $14.95 | 2023 | Panzyga |
| Fennec Pharmaceuticals, INC. | $14.79 | 2024 | Pedmark |
| Ipsen Biopharmaceuticals, INC | $14.58 | 2022 | |
| Heron Therapeutics, INC. | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Eason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.